Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

NCT05987241 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05987241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05987241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 2, 2024
Completion date
September 2, 2030
Enrollment
992 (estimated)
Sites
502

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder urothelial carcinoma, muscle invasive renal pelvis urothelial carcinoma, muscle invasive ureter urothelial carcinoma, muscle invasive urethral urothelial carcinoma, stage ii bladder urothelial carcinoma ajcc v6 and v7, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iv bladder urothelial carcinoma ajcc v7